Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Vidya Browder"'
Autor:
Salvatore La Rosa, Vidya Browder, Annette C Bakker, Jaishri O Blakeley, Sharad K Verma, Ling M Wong, Jill Morris, Naba Bora
Publikováno v:
EMBO Molecular Medicine, Vol 12, Iss 1, Pp 1-6 (2019)
Abstract The time from identifying a drug target to a new drug approval is often measured in decades and can take even longer for therapies to treat rare diseases. In fact, 95% of rare diseases do not have a specific therapy approved at all. Coordina
Externí odkaz:
https://doaj.org/article/ac0f85391a4b48ffaa21221cfe7ef4e9
Autor:
Ling M. Wong, Sharad K. Verma, Jaishri O. Blakeley, Jill A. Morris, Naba Bora, Vidya Browder, Salvatore La Rosa, Annette Bakker
Publikováno v:
EMBO Molecular Medicine, Vol 12, Iss 1, Pp n/a-n/a (2020)
EMBO Molecular Medicine
EMBO Molecular Medicine
The time from identifying a drug target to a new drug approval is often measured in decades and can take even longer for therapies to treat rare diseases. In fact, 95% of rare diseases do not have a specific therapy approved at all. Coordinated effor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84751be67f9d5c18b61d26c73e3643e2
https://doaj.org/article/ac0f85391a4b48ffaa21221cfe7ef4e9
https://doaj.org/article/ac0f85391a4b48ffaa21221cfe7ef4e9
Autor:
Sharad K. Verma, Jaishri O. Blakeley, Ling M. Wong, Annette Bakker, Salvatore La Rosa, Vidya Browder, Naba Bora, Jill A. Morris
The time from target identification to new drug approval is often measured in decades. This can be even more challenging for rare diseases. Indeed, 95% of rare diseases do not have a specific therapy approved. Coordinated efforts to support research
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51967a791af43c99c25771e070995736
https://doi.org/10.1101/552976
https://doi.org/10.1101/552976
Autor:
Sharad K. Verma, Jaishri O. Blakeley, Jill A. Morris, Annette Bakker, Vidya Browder, Naba Bora, Salvatore La Rosa, Ling M. Wong
Publikováno v:
Cancer Research. 80:2057-2057
The time from identifying a drug target to a new drug approval is often measured in decades and can take even longer for therapies to treat rare diseases. In fact, 95% of rare diseases do not have a specific therapy approved at all. Coordinated effor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e74040e377a48b5e7224de64b0fa30dd
https://doi.org/10.1158/1538-7445.am2020-2057
https://doi.org/10.1158/1538-7445.am2020-2057